

Ulcerative Colitis: Therapy or Disease Association with Cancer Development

Cassidy Eby^{1*}, Hunter Eby², Mani K. Askari³

¹Resident, Division of Internal Medicine, Department of Medicine, 3000 Arlington Avenue, The University of Toledo, Toledo OH 43615

²College of Medicine and Life Sciences, 3000 Arlington Avenue, The University of Toledo, Toledo OH 43615

³Assistant Professor, Internal Medicine Clerkship Director, Division of Internal Medicine, Department of Medicine, 3000 Arlington Avenue, The University of Toledo, Toledo OH 43615

Email: cassidy.gillman@utoledo.edu

Received: 2024-07-03

Accepted: 2024-09-08

Published: 2025-06-30

Ulcerative colitis is an immune-mediated disease, a dysregulation of the immune-response that results in inflammation and triggers an inflammatory reaction in the colonic mucosa (1). In ulcerative colitis, there are three circumstances in which cancer can arise. The first circumstance is related to the disease, the chronic inflammation of UC puts individuals with UC at 5.7 times higher risk of developing colorectal cancer than the general population (2,3). The second circumstance is due to treatments related to the UC causing cancer, this is what this manuscript covers. Finally, the third circumstance is cancer not related to UC or the treatment of UC (3). Since the mechanism of ulcerative colitis leading to colorectal cancer is not known. It is important to mitigate the risk of cancer if possible and try to avoid treatments that increase an individual's risk of cancer. This review covers the different treatments plans used based on the severity of the disease and their malignancy risk.

Keywords: Gastroenterology, Oncology, Cancer, Ulcerative Colitis, Immune-Mediated, Inflammatory Bowel Disease

References

1. Fries, W., Comunale, S. *Ulcerative colitis: pathogenesis*. Curr Drug Targets, 2011. **12**(10): p. 1373-82.
2. Bajpai, M., Seril, D. N., Van Gurp, J., Geng, X., Alvarez, J., Minacapelli, C. D., Gorin, S., Das, K. K., Poplin, E., Cheng, J., Amenta, P. S., Das, K. M. *Effect of Long-Term Mesalamine Therapy on Cancer-Associated Gene Expression in Colonic Mucosa of Patients with Ulcerative Colitis*. Digestive Diseases and Sciences, 2019. **64**(3): p. 740-750.

3. Jauregui-Amezaga, A., S. Vermeire, and H. Prenen. *Use of biologics and chemotherapy in patients with inflammatory bowel diseases and cancer*. Ann Gastroenterol, 2016. **29**(2): p. 127-36.